DAE HWA Pharm

067080 · KOSDAQ · Health Care · SMALL CAP

A new supply contract.

DAE HWA Pharm disclosed a supply contract, worth US$8.88M, about 8.59% of its recent annual revenue, running through Oct 2026.

Supply contract(Supply contract terminated)· FILED 2026-09-14· RCEPT 20260914900339

US$8.88MContract value
8.59%vs. recent revenue
Oct 2026Throughfrom Oct 2016

Converted at 1 USD ≈ ₩1,345.61 (filing-date rate, 2026-09-14 close)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-09-18) →

What happened

DAE HWA Pharm disclosed a supply contract, worth US$8.88M, about 8.59% of its recent annual revenue, running through Oct 2026.

For context, this single contract equals about 8.59% of the company's most recent annual revenue.

CounterpartyDisclosed
Contract valueUS$8.88M
vs. recent revenue8.59%
ThroughOct 2026 (from Oct 2016)
Filed2026-09-14, Supply contract terminated
SourceDART rcept 20260914900339 → open original filing

Versions of this filing

  1. 2026-09-14Original (this page)
  2. 2026-09-18Amendment 1

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-09-14 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.